Search

everythinglearnresearchcommunity

for

Search:↓

Advanced nanocarrier and microneedle drug delivery methods are more effective, safer, and less invasive for treating skin diseases.

People with alopecia areata have more Th17 cells and fewer Treg cells, which may be key to the condition's development.

Lymphocytes, especially CD8+ T cells, play a key role in causing alopecia areata, and targeting them may lead to new treatments.

Alopecia areata, a type of hair loss, is likely an autoimmune disease with a genetic link, but its exact cause is still unknown.

Certain immune cells contribute to severe hair loss in chronic alopecia areata, with Th17 cells possibly having a bigger impact than cytotoxic T cells.

People with certain types of alopecia have a slightly higher risk of cancer, especially thyroid, bladder, and prostate cancers.

People with alopecia areata have higher levels of osteopontin, which might be important in the disease's development, but this doesn't relate to how severe the disease is.

T cells and bacteria in the gut and skin help maintain health and protect against disease.

Higher IL-17A levels indicate more severe alopecia areata.

BST2 protein and certain T cells increase in early alopecia areata.

The study concluded that immune cells attacking hair follicles cause hair loss in alopecia, with genetics and environment also playing a role, and highlighted the potential of certain treatments.

Alopecia areata in elderly people is usually mild and responds well to treatment.

Recent findings suggest that genetic factors, immune system issues, and skin cell defects might contribute to the development of hidradenitis suppurativa.

Hair loss from Alopecia Areata is caused by both genes and environment, with several treatments available but challenges in cost and relapse remain.

New treatments focusing on immune pathways show promise for stubborn hair loss.

The guidelines suggest using various treatments, including antidepressants and steroids, for alopecia areata and discuss the condition's genetic and immune aspects.

A substance called miR-1246 may help treat severe hair loss by reducing certain immune cell activities.

Minoxidil and finasteride are the only FDA-approved treatments for hair loss caused by genetic and hormonal factors, but their effectiveness is often doubted, indicating a need for new treatments.

Alopecia areata needs more recognition and better treatment access in Latin America to improve patient care and outcomes.

Hair follicle-derived IL-7 and IL-15 are crucial for maintaining skin-resident memory T cells and could be targeted for treating skin diseases and lymphoma.

Alopecia areata involves immune activation in the scalp, suggesting treatments targeting TH1, TH2, and IL-23 pathways.

Memory regulatory T cells need IL-7, not IL-2, to stay in peripheral tissues.

UVB exposure in human skin causes macrophages to produce more IL-10 and less IL-12, leading to immunosuppression.

Blocking IL-12/IL-23p40 helped reverse severe hair loss in patients.

Equisetum debile extract, especially the ethyl acetate type, may be a promising natural ingredient for anti-hair loss products.

IL-4 gene variation may increase the risk of alopecia areata in Turkish people.

IL-3 worsens lupus nephritis and blocking it improves kidney health.

A protein called IL-36γ causes skin side effects from certain cancer treatments when combined with a common skin bacteria.

IL-1 alpha stops hair follicle growth and hair production.